Evidence map›Paper›PMID 38467476›Full record

ArticleESC heart failure2024

Immediate pharmacotherapy intensification after cardiac resynchronization therapy: incidence, characteristics, and impact.

Kojiro Ogawa, Hiro Yamasaki, Kazutaka Aonuma, Masafumi Otani, Ai Hattori, Masako Baba, Kentaro Yoshida, Miyako Igarashi, Hidetaka Nishina, Kou Suzuki and 2 more

Abstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kojiro OgawaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.ORCID https://orcid.org/0000-0002-3298-6586
Hiro YamasakiDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Kazutaka AonumaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Masafumi OtaniDepartment of Cardiology, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Ai HattoriDepartment of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Masako BabaDepartment of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Kentaro YoshidaDepartment of Cardiology, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Miyako IgarashiDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Hidetaka NishinaDepartment of Cardiology, Tsukuba Medical Center Hospital, Tsukuba, Japan.
Kou SuzukiDepartment of Cardiology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.
Akihiko NogamiDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
Masaki IedaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsCardiac resynchronization therapy (CRT) is an established treatment for drug-refractory heart failure (HF) in patients with left bundle branch block (LBBB). Acute haemodynamic improvement after CRT implantation may enable the intensification of HF medication soon thereafter. Immediate pharmacotherapy intensification (IPI) after CRT implantation achieves a synergetic effect, possibly leading to a better prognosis. This study aimed to explore the incidence, characteristics, and impact of IPI on real-world outcomes among CRT recipients with a history of hospitalization for acute HF. METHODS AND

resultsThis multicentre retrospective study enrolled CRT recipients with LBBB morphology, a QRS width ≥120 ms, a left ventricular ejection fraction ≤35%, and New York Heart Association II-IV HF symptoms. All patients had previous HF hospitalizations within the previous year and received guideline-directed medical therapy before CRT implantation. Patient baseline characteristics, including HF medication, were collected. IPI was defined as the intensification of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists within 30 days of CRT implantation. The primary endpoint was all-cause death or first hospitalization for HF; the secondary endpoint was all-cause death. We enrolled 194 patients (75% male; mean age, 65 ± 13 years; 78% with non-ischaemic cardiomyopathy). One hundred five (54%) patients received IPI. Patients who received IPI exhibited a significantly shorter QRS duration (159 ± 26 vs. 171 ± 32 ms; P = 0.004), higher estimated glomerular filtration rate (55.2 ± 20.0 vs. 47.8 ± 24.7 mL/min/1.73 m

conclusionsImmediate intensification of HF medication was achieved in 54% of CRT recipients and was significantly higher in patients without excessive QRS prolongation, preserved renal function, and dilated cardiomyopathy than others. In patients with LBBB morphology and QRS ≥ 120 ms, IPI was associated with a significantly better prognosis and fewer HF hospitalizations after CRT implantation than others.

Indexed as

Cardiac Resynchronization TherapyHeart FailureAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBundle-Branch BlockFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMineralocorticoid Receptor AntagonistsRetrospective StudiesStroke VolumeAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsMineralocorticoid Receptor AntagonistsCardiac resynchronization therapyHeart failureImmediate pharmacotherapy intensificationLeft bundle branch blockPrognosis

Identifiers

PMID38467476
PMCPMC11287365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.